Urotronic’s drug-coated balloon technology is utilised in interventional urology to treat urethral strictures and benign prostatic hyperplasia. Credit: JAFAR AHMED on Unsplash.

Laborie Medical Technologies has concluded the previously announced acquisition of medical device company Urotronic.

In September of this year, Laborie first signed an agreement to acquire Urotronic in a transaction valued at up to $600m.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The deal includes a $255m upfront cash payment and up to another $345m in potential commercial and reimbursement milestone payments.

As part of the transaction, Urotronic and its employees will be completely integrated into Laborie.

Laborie president and CEO Michael Frazzette said: “We are delighted to welcome the Urotronic team to Laborie and we look forward to working together in our mission to deliver innovative technologies in the Interventional Urology space that preserve and restore human dignity.”

See Also:

Urotronic developed Optilume drug-coated balloon technology that is used in interventional urology for the treatment of urethral strictures and benign prostatic hyperplasia (BPH) or enlarged prostate conditions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It is a new minimally invasive surgical therapy that integrates mechanical dilation with the delivery of paclitaxel for the treatment of lower urinary tract symptoms secondary to urological BPH stricture.

The company received approval from the US Food and Drug Administration and CE Mark for its Optilume products.

Urotronic president and CEO David Perry said: “Over the last several years, we have seen our partnership develop because we are united on a goal to improve the standard of care for patients and commercialise Optilume products on a global stage.”